Pharmacogenetics of the arylamine N-acetyltransferases: A Symposium in Honor of Wendell W. Weber

This article is a report on a symposium sponsored by the American Society f or Pharmacology and Experimental Therapeutics presented at the joint meetin g of the American Society for Biochemistry and Molecular Biology and the Am erican Society for Pharmacology and Experimental Therapeutics, June 4-8, Bo ston, Massachusetts. The presentations focused on the pharmacogenetics of t he NAT1 and NAT2 arylamine N-acetyltransferases, including developmental re gulation, structure-function relationships, and their possible role in susc eptibility to breast, colon, and pancreatic cancers. The symposium honored Wendell W. Weber for over 35 years of leadership and scientific advancement in pharmacogenetics and was highlighted by his overview of the historical development of the field.